An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

580

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Alzheimer's Disease
Interventions
DRUG

Placebo

Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.

DRUG

Galantamine 16 mg/day

Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.

DRUG

Galantamine 24 mg/day

Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.

Trial Locations (1)

Unknown

Fukuoka

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT00814801 - An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter